Novitas says Pacific Edge’s CxBladder tests are ‘not payable’

Novitas says Pacific Edge’s CxBladder tests are ‘not payable’
The company can continue to apply for renewed coverage. (Image: Pacific Edge)
Rebecca Howard
The long-awaited draft Local Coverage Determination from Novitas is not good news for Pacific Edge’s US business. According to the determination (LCD), “CxBladder tests are not reasonable and necessary to support positive outcomes in the management of bladder cancer and, therefore, are not payable”.In June 2023, Pacific Edge confirmed that the LCD from Novitas — its Medicare administrative contractor — meant its flagship Cxbladder test for bladder cancer didn’t meet the threshold required for coverage un...

More Markets

NZ sharemarket closes lower, tech stocks buoyed by Oracle update
Markets Market Close

NZ sharemarket closes lower, tech stocks buoyed by Oracle update

The S&P/NZX 50 Index closed down 0.35% or 47.09 points.

Tom Raynel 11 Sep 2025
How RFK Jnr's Medicare reform could aid this NZ firm
Markets

How RFK Jnr's Medicare reform could aid this NZ firm

'Wild west' conditions hampered its US push. They could be changing.

Average home insurance tops $2,000
Infrastructure Risky Business

Average home insurance tops $2,000

Insurance premiums in New Zealand have increased dramatically in recent years.

Michael Neilson 11 Sep 2025